CD274 and non-small cell lung carcinoma: Currently, evidence suggests that the OS benefit from monotherapy was mainly observed in patients with high PD-L1 expression (PD-L1 TPS≥50%) in first-line therapies for advanced NSCLC, such as pembrolizumab in KEYNOTE 024, atezolizumab in IMpower 110 or cemiplimab in EMPOWER-Lung [5, 6, 8, 9].